Gujarat Themis Biosyn Limited has informed the Exchange that Board of Directors at its meeting held on May 20, 2025, recommended Final Dividend of 0.67 per equity share.
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Themis Biosyn's board, at its May 20, 2025 meeting, approved audited results for Q4 and FY ended March 31, 2025. FY25 total income fell to Rs. 15,323 lakhs from Rs. 17,419 lakhs a year earlier, and net profit declined to Rs. 4,877 lakhs (from Rs. 5,916 lakhs); FY25 EPS stood at Rs. 4.48 (restated post-bonus) versus Rs. 5.43. The board recommended a final dividend of Rs. 0.67 per share (67% on Re. 1 face value), totalling about Rs. 7.30 crore, subject to shareholder approval. It also appointed M/s. KRS AND Co. as Secretarial Auditor for five years (FY26–FY30) and re-appointed M/s. Raja Dutta & Co. as Cost Auditor for FY26. The company spent Rs. 11,615 lakhs on capex during the year, reflecting major capacity expansion.
Despite a decline in revenue and profit, shareholders are being rewarded with a 67% dividend on face value and the auditor appointments are routine. The bigger picture items to watch are the heavy capex underway and the earlier-approved amalgamation with Themis Medicare Limited, which could materially reshape the company once effective.